Efficacy and impact on cancer treatment of SARS-CoV-2 vaccination for breast cancer patients: multi-center prospective observational study

Efficacy and impact on cancer treatment of SARS-CoV-2 vaccination for breast cancer patients: multi-center prospective observational study - Efficacy and impact on cancer treatment of SARS-CoV-2 vaccination for breast cancer patients: multi-center prospective observational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045527

Enrollment

100

Registered

2021-09-21

Start date

2021-05-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with pathologically diagnosed breast cancer 2) Patients who are on drug therapy for breast cancer or plan to be on drug therapy at the time of vaccination. 3) Patients who have not been vaccinated with SARS-CoV-2 vaccine and plan to be vaccinated during the enrollment period. 4) Patients aged 20 years or older on the date of enrollment, with a Performance Status (PS) of 0-3 5) Patients who have given written consent to participate in this study

Exclusion criteria

Exclusion criteria: 1) Patients with a history of COVID-19 by the date of study enrollment 2) Patients with inappropriate SARS-CoV-2 vaccination 3) Other patients deemed unsuitable as subjects by the principal investigator

Design outcomes

Primary

Measure	Time frame
Titer of antibody against SARS-CoV-2 S protein in serum after 4 weeks from vaccination	—

Secondary

Measure	Time frame
Effect on treatment related vaccination	—

Countries

Japan

Contacts

Public ContactMitsuo Terada

Nagoyacity University Department of breast surgery

breast@med.nagoya-cu.ac.jp052-851-5511

Outcome results